News >

Atezolizumab Prolongs Survival in SCLC

Kristie L. Kahl
Published: Tuesday, Sep 25, 2018

Stephen V. Liu, MD

Stephen V. Liu, MD

The addition of atezolizumab (Tecentriq) to standard carboplatin and etoposide in the frontline setting significantly prolonged survival in patients with extensive-stage small cell lung cancer (ES-SCLC) compared with the chemotherapy regimen alone.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x